Prevention and treatment of glucocorticoid-induced osteoporosis in 2005.
Concern about glucocorticoid-induced osteoporosis is warranted in all patients who take glucocorticoids for longer than 3 months, in any dosage. Bone mineral density should be measured and additional risk factors sought in order to determine whether bisphosphonate therapy is appropriate. Bisphosphonate therapy should be considered in postmenopausal women and in patients whose bone densitometry T-score is less than -1.5.